Cargando…
A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol
Type 2 diabetes mellitus (T2DM) is a common chronic condition with significant health and socioeconomic consequences. In Nepal, T2DM is a common disease for which people consult ayurvedic (traditional medical system) practitioners and use ayurvedic medicines. Strong concerns remain about the subopti...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704971/ https://www.ncbi.nlm.nih.gov/pubmed/36451377 http://dx.doi.org/10.1097/MD.0000000000031452 |
_version_ | 1784840178135728128 |
---|---|
author | Chattopadhyay, Kaushik Dhimal, Meghnath Karki, Shristi Regmi, Prerok Bista, Bihungum Biswas, Tuhin Kanti Heinrich, Michael Panniyammakal, Jeemon Tandon, Nikhil Leonardi-Bee, Jo Kinra, Sanjay Greenfield, Sheila Margaret Lewis, Sarah Anne Upadhyay, Vasudev Gyanwali, Pradip |
author_facet | Chattopadhyay, Kaushik Dhimal, Meghnath Karki, Shristi Regmi, Prerok Bista, Bihungum Biswas, Tuhin Kanti Heinrich, Michael Panniyammakal, Jeemon Tandon, Nikhil Leonardi-Bee, Jo Kinra, Sanjay Greenfield, Sheila Margaret Lewis, Sarah Anne Upadhyay, Vasudev Gyanwali, Pradip |
author_sort | Chattopadhyay, Kaushik |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM) is a common chronic condition with significant health and socioeconomic consequences. In Nepal, T2DM is a common disease for which people consult ayurvedic (traditional medical system) practitioners and use ayurvedic medicines. Strong concerns remain about the suboptimal T2DM management of many patients by ayurvedic practitioners, and therefore, based on the best available scientific evidence, we have developed a clinical guideline for managing T2DM by ayurvedic practitioners. The research question to be addressed by a definitive cluster randomized controlled trial (RCT) is whether the introduction of a clinical guideline can improve the management of T2DM by ayurvedic practitioners in Nepal as compared to usual ayurvedic management (i.e., without any clinical guideline). In preparation for this future work, this current study aims to determine the feasibility of undertaking the definitive cluster RCT. METHODS: This is a 2-arm, feasibility cluster RCT with a blinded outcome assessment and a qualitative evaluation. The study is conducted in 12 public and private ayurveda centers in and outside the Kathmandu Valley in Nepal (1:1 intervention:control). Eligible participants should be new T2DM adult patients (i.e., treatment naïve) - the glycated hemoglobin level should be 6.5% or above but less than 9%. At least 120 participants (60/group) will be recruited and followed up for 6 months. Important parameters, needed to design the definitive trial, will be estimated, such as the standard deviation of the outcome measure (i.e., glycated hemoglobin level at 6-month follow-up), intraclass correlation coefficient, cluster size, recruitment, the time needed to recruit participants, follow-up, and adherence to the recommended ayurvedic medicine. Semi-structured qualitative interviews will be conducted with around 20 to 30 participants and all the participating ayurvedic practitioners to explore their experiences and perspectives of taking part in the study and of the intervention and a sample of eligible people declining to participate in the study to explore the reasons behind nonparticipation. DISCUSSION: We are now conducting a feasibility cluster RCT in Nepal to determine the feasibility of undertaking the definitive cluster trial. The first participant was recruited on 17 July 2022. If the feasibility is promising (such as recruitment, follow-up, and adherence to the recommended ayurvedic medicine), then the parameters estimated will be used to design the definitive cluster trial. Decisions over whether to modify the protocol will mainly be informed by the qualitative data. |
format | Online Article Text |
id | pubmed-9704971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97049712022-11-29 A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol Chattopadhyay, Kaushik Dhimal, Meghnath Karki, Shristi Regmi, Prerok Bista, Bihungum Biswas, Tuhin Kanti Heinrich, Michael Panniyammakal, Jeemon Tandon, Nikhil Leonardi-Bee, Jo Kinra, Sanjay Greenfield, Sheila Margaret Lewis, Sarah Anne Upadhyay, Vasudev Gyanwali, Pradip Medicine (Baltimore) 3800 Type 2 diabetes mellitus (T2DM) is a common chronic condition with significant health and socioeconomic consequences. In Nepal, T2DM is a common disease for which people consult ayurvedic (traditional medical system) practitioners and use ayurvedic medicines. Strong concerns remain about the suboptimal T2DM management of many patients by ayurvedic practitioners, and therefore, based on the best available scientific evidence, we have developed a clinical guideline for managing T2DM by ayurvedic practitioners. The research question to be addressed by a definitive cluster randomized controlled trial (RCT) is whether the introduction of a clinical guideline can improve the management of T2DM by ayurvedic practitioners in Nepal as compared to usual ayurvedic management (i.e., without any clinical guideline). In preparation for this future work, this current study aims to determine the feasibility of undertaking the definitive cluster RCT. METHODS: This is a 2-arm, feasibility cluster RCT with a blinded outcome assessment and a qualitative evaluation. The study is conducted in 12 public and private ayurveda centers in and outside the Kathmandu Valley in Nepal (1:1 intervention:control). Eligible participants should be new T2DM adult patients (i.e., treatment naïve) - the glycated hemoglobin level should be 6.5% or above but less than 9%. At least 120 participants (60/group) will be recruited and followed up for 6 months. Important parameters, needed to design the definitive trial, will be estimated, such as the standard deviation of the outcome measure (i.e., glycated hemoglobin level at 6-month follow-up), intraclass correlation coefficient, cluster size, recruitment, the time needed to recruit participants, follow-up, and adherence to the recommended ayurvedic medicine. Semi-structured qualitative interviews will be conducted with around 20 to 30 participants and all the participating ayurvedic practitioners to explore their experiences and perspectives of taking part in the study and of the intervention and a sample of eligible people declining to participate in the study to explore the reasons behind nonparticipation. DISCUSSION: We are now conducting a feasibility cluster RCT in Nepal to determine the feasibility of undertaking the definitive cluster trial. The first participant was recruited on 17 July 2022. If the feasibility is promising (such as recruitment, follow-up, and adherence to the recommended ayurvedic medicine), then the parameters estimated will be used to design the definitive cluster trial. Decisions over whether to modify the protocol will mainly be informed by the qualitative data. Lippincott Williams & Wilkins 2022-11-25 /pmc/articles/PMC9704971/ /pubmed/36451377 http://dx.doi.org/10.1097/MD.0000000000031452 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 3800 Chattopadhyay, Kaushik Dhimal, Meghnath Karki, Shristi Regmi, Prerok Bista, Bihungum Biswas, Tuhin Kanti Heinrich, Michael Panniyammakal, Jeemon Tandon, Nikhil Leonardi-Bee, Jo Kinra, Sanjay Greenfield, Sheila Margaret Lewis, Sarah Anne Upadhyay, Vasudev Gyanwali, Pradip A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol |
title | A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol |
title_full | A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol |
title_fullStr | A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol |
title_full_unstemmed | A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol |
title_short | A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol |
title_sort | clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in nepal: a feasibility cluster randomized controlled trial protocol |
topic | 3800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704971/ https://www.ncbi.nlm.nih.gov/pubmed/36451377 http://dx.doi.org/10.1097/MD.0000000000031452 |
work_keys_str_mv | AT chattopadhyaykaushik aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT dhimalmeghnath aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT karkishristi aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT regmiprerok aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT bistabihungum aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT biswastuhinkanti aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT heinrichmichael aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT panniyammakaljeemon aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT tandonnikhil aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT leonardibeejo aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT kinrasanjay aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT greenfieldsheilamargaret aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT lewissarahanne aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT upadhyayvasudev aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT gyanwalipradip aclinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT chattopadhyaykaushik clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT dhimalmeghnath clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT karkishristi clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT regmiprerok clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT bistabihungum clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT biswastuhinkanti clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT heinrichmichael clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT panniyammakaljeemon clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT tandonnikhil clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT leonardibeejo clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT kinrasanjay clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT greenfieldsheilamargaret clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT lewissarahanne clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT upadhyayvasudev clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol AT gyanwalipradip clinicalguidelinebasedmanagementoftype2diabetesbyayurvedicpractitionersinnepalafeasibilityclusterrandomizedcontrolledtrialprotocol |